Recombinant FXIII (rFXIII-A (2) ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency

Recombinant factor XIII-A (2) (rFXIII-A (2) ) was developed for prophylaxis and treatment of bleeds in patients with congenital FXIII A-subunit deficiency. mentor™2 (NCT00978380), a multinational, open-label, single-arm, multiple-dosing extension to the pivotal mentor™1 trial, assessed long-term saf...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Thromb Haemost
Hoofdauteurs: Carcao, Manuel, Altisent, Carmen, Castaman, Giancarlo, Fukutake, Katsuyuki, Kerlin, Bryce A., Kessler, Craig, Lassila, Riitta, Nugent, Diane, Oldenburg, Johannes, Garly, May-Lill, Rosholm, Anders, Inbal, Aida
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Schattauer GmbH 2018
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6260112/
https://ncbi.nlm.nih.gov/pubmed/29448295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0038-1624581
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items